Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial

医学 射频消融术 肝细胞癌 危险系数 临床终点 放射外科 总体生存率 随机对照试验 放射科 内科学 核医学 放射治疗 烧蚀 置信区间
作者
Mian Xi,Zhoutian Yang,Li Hu,Yizhen Fu,Dandan Hu,Zhongguo Zhou,Shiliang Liu,Jing Zhao,Jingxian Shen,Qiaoqiao Li,Baoqing Chen,Li Xu,Aiping Fang,Minshan Chen,Shiliang Liu,Yaojun Zhang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
被引量:8
标识
DOI:10.1200/jco-24-01532
摘要

PURPOSE To assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC). METHODS In this trial, patients with recurrent small HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA. The primary end point was local progression-free survival (LPFS), and secondary end points were progression-free survival (PFS), overall survival (OS), local control rate, and safety. RESULTS Between August 2019 and April 2022, 166 patients were assigned to SBRT (n = 83) and RFA (n = 83) groups. After a median follow-up time of 42.8 and 42.9 months in the SBRT and RFA groups, respectively, SBRT demonstrated a significantly better LPFS than that of RFA (hazard ratio [HR], 0.45 [95% CI, 0.24 to 0.87]; P = .014). The 2-year LPFS rates were 92.7% (95% CI, 87.3 to 98.5) with SBRT and 75.8% (95% CI, 67.2 to 85.7) with RFA. The median PFS time of the SBRT and RFA groups was 37.6 (95% CI, 26.0 to 49.2) and 27.6 (95% CI, 20.3 to 34.8) months, respectively (HR, 0.76 [95% CI, 0.50 to 1.15]; P = .190). Nine patients in the SBRT group and 10 in the RFA group died during the follow-up. The 2-year OS rates were 97.6% (95% CI, 94.3 to 100.0) in the SBRT group and 93.9% (95% CI, 88.9 to 99.2) in the RFA group (HR, 0.91 [95% CI, 0.37 to 2.22]; P = .830). The incidences of both acute and late adverse events were comparable between the groups ( P = .436 and P = .715, respectively). CONCLUSION SBRT achieved better LPFS than that of RFA in patients with single recurrent HCC ≤5 cm, especially in HCC ≤2 cm, whereas PFS, OS, and safety were comparable between the two treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
花生王子完成签到 ,获得积分10
刚刚
D-L@rabbit完成签到 ,获得积分10
1秒前
GankhuyagJavzan完成签到,获得积分10
1秒前
5秒前
稚祎完成签到 ,获得积分10
7秒前
9秒前
弧光完成签到 ,获得积分0
13秒前
dmm完成签到 ,获得积分10
14秒前
佳期如梦完成签到 ,获得积分10
16秒前
展会恩完成签到,获得积分10
16秒前
干将莫邪完成签到,获得积分10
17秒前
执着夏岚完成签到 ,获得积分10
20秒前
20秒前
23秒前
lhn完成签到 ,获得积分10
23秒前
饱满烙完成签到 ,获得积分10
24秒前
菓小柒完成签到 ,获得积分10
24秒前
26秒前
27秒前
hongxing liu发布了新的文献求助10
32秒前
Dongjie发布了新的文献求助10
34秒前
杨永佳666完成签到 ,获得积分10
35秒前
Lisztan完成签到,获得积分10
38秒前
Tysonqu完成签到,获得积分10
38秒前
萤火虫完成签到,获得积分10
39秒前
饱满的新之完成签到 ,获得积分10
41秒前
songyu完成签到,获得积分10
42秒前
42秒前
黑苹果完成签到,获得积分10
44秒前
孙总完成签到,获得积分10
45秒前
健壮仙人掌完成签到,获得积分10
48秒前
鲸鱼打滚完成签到 ,获得积分10
49秒前
传奇3应助科研通管家采纳,获得10
52秒前
hongxing liu完成签到,获得积分10
54秒前
紫金之巅完成签到 ,获得积分10
55秒前
快乐的90后fjk完成签到 ,获得积分10
56秒前
漂亮的忆文完成签到,获得积分10
1分钟前
蜗牛完成签到 ,获得积分10
1分钟前
科研通AI2S应助hongxing liu采纳,获得10
1分钟前
haochi完成签到,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167370
捐赠科研通 3248804
什么是DOI,文献DOI怎么找? 1794465
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664